Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRD4 | O60885 | 5/20 | 0.58 |
| ▸ | CA2 | P00918 | 7/20 | 0.49 |
| ▸ | CA9 | Q16790 | 6/20 | 0.49 |
| ▸ | CA12 | O43570 | 4/20 | 0.49 |
| ▸ | MAOB | P27338 | 3/20 | 0.48 |
| ▸ | MAOA | P21397 | 2/20 | 0.48 |
| ▸ | CA1 | P00915 | 6/20 | 0.47 |
| ▸ | CA13 | Q8N1Q1 | 2/20 | 0.46 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.44 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20506998 | 0.79 | BRD4 (0.61) | BRD4CA2CA9CA12MAOB | |
| SCHEMBL16658396 | 0.77 | BRD4 (0.54) | BRD4CA2CA9CA12CA1 | |
| SCHEMBL28032548 | 0.76 | CA2 (0.73) | CA2CA9CA12CA1CA13 | |
| SCHEMBL13680661 | 0.76 | BRD4 (0.64) | BRD4 | |
| SCHEMBL22802355 | 0.75 | CA2 (0.45) | BRD4CA2CA9CA12CA1 | |
| SCHEMBL19280560 | 0.74 | BRD4 (0.62) | BRD4 | |
| SCHEMBL6850257 | 0.74 | MAOA (0.68) | CA2CA9CA12MAOBMAOA | |
| SCHEMBL16650561 | 0.74 | BRD4 (1.00) | BRD4 | |
| SCHEMBL9919107 | 0.73 | BRD4 (0.59) | BRD4 | |
| SCHEMBL1926937 | 0.73 | CA2 (0.67) | CA2CA9CA12CA1CA13 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10562915-B2 | Bromodomain inhibitors | CELGENE QUANTICEL RESEARCH, INC. (US) | 2020-02-18 | — | — | US | disclosed |
| US-20180273547-A1 | BROMODOMAIN INHIBITORS | CELGENE QUANTICEL RES INC (US) | 2018-09-27 | — | — | US | disclosed |
| US-9288869-B2 | Styryl-based compound, composition containing styryl-based compound, and organic light emitting diode including styryl-based compound | SAMSUNG DISPLAY CO., LTD. (KR) | 2016-03-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10562915-B2 | Bromodomain inhibitors | BRD3, EP300, BRPF3 | BRD4 5/4885CA2 3892/4885CA9 3995/4885 |
| US-20180273547-A1 | BROMODOMAIN INHIBITORS | BRD3, EP300, BRPF3 | BRD4 5/4885CA2 3892/4885CA9 3995/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.